Octreotide

Form: Subcutaneous Injection; IV Infusion

Strength: SQ: (0.5 mg/mL, 1 mg/mL, 3 mg/mL), Infusion: 0.25 mg/mL

Reference Brands: Sandostatin® , Sandostatin®

Category: Oncology Cancer Care

Octreotide, marketed under the brand name Sandostatin®, is a somatostatin analogue used in oncology to manage carcinoid tumors, acromegaly, and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Available as subcutaneous injections (0.5 mg/mL, 1 mg/mL, 3 mg/mL) and long-acting injections (Sandostatin LAR®) (10 mg, 20 mg, 30 mg), it works by inhibiting hormone secretion, controlling tumor-induced symptoms like diarrhea and flushing. Sourced from GMP-certified suppliers, Octreotide is widely available for global distribution in US and EU markets. It provides reliable therapeutic options for oncologists and healthcare providers treating complex neuroendocrine tumors.